Dr. Reddy’s Laboratories shares jump over 1% as European Commission approves biosimilar AVT03
[hfe_template id='11223']
[ad_1]
Dr. Reddy’s Laboratories shares jumped 1.5% to their day’s low of Rs 1242.90 on the BSE on Tuesday, November 25, after the company announced that the European Commission (EC) has granted marketing authorization for AVT03, a proposed biosimilar of Prolia and Xgeva. In an official statement dated November 24, the company said the authorization covers all EU Member States as well as countries within the European Economic Area, including Iceland, Liechtenstein and Norway. AVT03 (denosumab) is indicated for conditions such as osteoporosis in postmenopausal women and bone-related complications arising from advanced cancers, based on the referenced products Prolia and Xgeva. The approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) in September 2025. According to the company, the decision was supported by analytical comparisons, pharmacokinetic and pharmacodynamic assessments, and outcomes from...